Subscribe To
REGN / Regeneron CEO on the prospects for its eye drug Eylea
REGN News
By Market Watch
November 2, 2023
Regeneron Pharma's adjusted earnings beat estimates
Regeneron Pharmaceuticals Inc.'s stock REGN, +1.46% rose fractionally on Thursday after the drug maker said its profit dropped by 23%, while its adjus more_horizontal
By Reuters
November 2, 2023
Regeneron beats quarterly profit estimates on eczema treatment strength
Regeneron Pharmaceuticals on Thursday beat Wall Street estimates for third-quarter profit, driven by strong demand for its eczema treatment Dupixent. more_horizontal
By Zacks Investment Research
November 1, 2023
Curious about Regeneron (REGN) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understandi more_horizontal
By The Motley Fool
October 16, 2023
2 Healthcare Stocks Near 52-Week Highs Still Worth Buying
Healthcare stocks, on balance, haven't been great investments in 2023. Regeneron Pharmaceuticals and Vertex Pharmaceuticals have been two glaring exce more_horizontal
By Zacks Investment Research
October 6, 2023
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely bea more_horizontal
By The Motley Fool
October 5, 2023
This Market-Beating Stock Just Gave Investors More Reasons to Invest
Regeneron recently earned a key regulatory approval. The company also expanded its pipeline with an acquisition. more_horizontal
By GlobeNewsWire
September 28, 2023
Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023
TARRYTOWN, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quart more_horizontal
By The Motley Fool
September 20, 2023
This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost
Regeneron's sales growth rate has been struggling over the past year. Revenue from its top-selling drug, Eylea, fell 7% in the most recent quarter. more_horizontal